Archives of Clinical Infectious Diseases

Published by: Kowsar

Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis

Mitra Barati 1 , * , Mehdi Shekarabi 1 , Saeed Chobkar 2 , Mahshid Talebi-Taher 3 and Newsha Farhadi 4
Authors Information
1 Pediatric Infectious Diseases Research Centre, Iran University of Medical Sciences, Tehran, IR Iran
2 Department of Internal Medicine, Iran University of Medical Sciences,Tehran, IR Iran
3 Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, IR Iran
4 Medical Faculty, Shahed University, Tehran, Iran
Article information
  • Archives of Clinical Infectious Diseases: January 30, 2015, 10 (1); e26346
  • Published Online: January 25, 2015
  • Article Type: Research Article
  • Received: September 23, 2014
  • Accepted: September 25, 2014
  • DOI: 10.5812/archcid.26346

To Cite: Barati M, Shekarabi M, Chobkar S, Talebi-Taher M, Farhadi N. Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis, Arch Clin Infect Dis. 2015 ; 10(1):e26346. doi: 10.5812/archcid.26346.

Abstract
Copyright © 2015, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Bochud PY, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ. 2003; 326(7383): 262-6[PubMed]
  • 2. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003; 29(4): 530-8[DOI][PubMed]
  • 3. Spapen HD, Hachimi-Idrissi S, Corne L, Huyghens LP. Diagnostic markers of sepsis in the emergency department. Acta Clin Belg. 2006; 61(3): 138-42[DOI][PubMed]
  • 4. Dekkers PE, ten Hove T, te Velde AA, van Deventer SJ, van Der Poll T. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun. 2000; 68(4): 2156-60[PubMed]
  • 5. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis. 1999; 58(8): 488-92[PubMed]
  • 6. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007; 11(2)[DOI][PubMed]
  • 7. Molkanen T, Ruotsalainen E, Thorball CW, Jarvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2011; 30(11): 1417-24[DOI][PubMed]
  • 8. Lawn SD, Myer L, Bangani N, Vogt M, Wood R. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. BMC Infect Dis. 2007; 7: 41[DOI][PubMed]
  • 9. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF, 3rd.. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood. 1995; 86(1): 203-11[PubMed]
  • 10. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009; 27(3): 157-72[DOI][PubMed]
  • 11. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012; 38(9): 1418-28[DOI][PubMed]
  • 12. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340(6): 448-54[DOI][PubMed]
  • 13. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003; 123(6): 2043-9[PubMed]
  • 14. Sierra R, Rello J, Bailen MA, Benitez E, Gordillo A, Leon C, et al. C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome. Intensive Care Med. 2004; 30(11): 2038-45[DOI][PubMed]
  • 15. Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care. 2004; 8(4)-42[DOI][PubMed]
  • 16. Boonstra MC, Verspaget HW, Ganesh S, Kubben FJ, Vahrmeijer AL, van de Velde CJ, et al. Clinical applications of the urokinase receptor (uPAR) for cancer patients. Curr Pharm Des. 2011; 17(19): 1890-910[PubMed]
  • 17. Jo M, Thomas KS, Wu L, Gonias SL. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem. 2003; 278(47): 46692-8[DOI][PubMed]
  • 18. Mizukami IF, Todd RF, 3rd.. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells. J Leukoc Biol. 1998; 64(2): 203-13[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments